NHS Halts Hormone Treatment for Questioning Teens Amid Evidence Concerns

NHS England has made public a pause on new prescriptions of cross-sex hormones for 16 and 17-year-olds exploring gender identity questions, following a thorough examination that determined previous research into the drugs’ efficacy and safety was inadequate. The decision, which takes effect immediately, comes after an impartial assessment of evidence ordered by the health service determined there was inadequate quality evidence to determine whether the hormones benefit or harm young people. Teenagers already receiving the treatment will continue their prescriptions, though clinicians will be asked to review their cases. NHS England said a small number of young people would be impacted by the pause and will be offered alternative forms of care at three gender clinics operated by the NHS for children serving England.

The Choice and Its Reach

The pause represents a significant shift in NHS England’s handling of gender-affirming medical care for adolescents. Cross-sex hormones, which assist those acquire physical characteristics associated with their desired gender, can result in permanent alterations including a lower voice, breast growth, or other permanent alterations. The decision to halt new prescribing comes from the NHS’s assessment that current evidence cannot definitively establish whether these treatments help or harm teenagers suffering from gender dysphoria. Professor James Palmer, National Medical Director for Specialised Services at NHS England, highlighted that the review had been “extremely thorough and intricate,” finally concluding that existing evidence does not support continued use of masculinising or feminising hormones for young people under 18.

NHS England has launched a 90-day public consultation starting Monday to collect additional feedback on the revised policy and review results. The NHS expects this consultation period will uncover any data that could have been missed during the initial review process. Current guidance already banned prescriptions for under-16s requesting gender-related treatment, so the new suspension essentially broadens restrictions to cover 16 and 17-year-olds. The NHS stressed its commitment to providing comprehensive support, stating that young people unable to access hormone therapy will be offered alternative care options through its three specialized gender clinics for children across England.

• Pause applies to new prescriptions for adolescents aged 16-17 only
• Young people presently taking hormones will proceed with existing treatment
• Clinicians will review current cases for continued appropriateness
• Alternative care available at three NHS gender clinics across the country

Evidence Assessment Results

The decision to pause hormone prescriptions stems directly from a comprehensive evidence review commissioned by NHS England, which assessed the scientific foundation for cross-sex hormone treatment in young people. The assessment, comprising ten independent assessments of various dimensions of testosterone and oestrogen use, uncovered significant gaps in the evidence supporting existing clinical practice. NHS England determined that the available evidence was inadequate to establish whether these therapies benefit or harm young people with gender dysphoria, rendering it unfeasible to justify continuing new prescriptions with confidence in their safety and efficacy.

This observation aligns with worries expressed in Dr Hilary Cass’s major April 2024 assessment on pediatric gender care, which noted “notably insufficient” research surrounding therapeutic approaches in this field. The Cass review prompted NHS England to undertake its own detailed evaluation of the scientific evidence. The resulting evaluation addressed various outcomes for young patients, including quality of life, psychological wellbeing, and general wellbeing. Rather than delaying for more research to emerge, NHS England chose to adopt a precautionary approach, halting new prescriptions while continuing to review feedback from campaigning organizations and medical professionals.

What the Research Showed

The 10 separate evidence reviews examined the effects of hormone hormones covering physical and mental outcomes for adolescents with a gender identity different from their sex at birth. Reviewers assessed existing literature on how these treatments impacted life quality, mental health status, and distress related to gender identity in young people. The process was deliberately comprehensive, seeking to leave no stone unturned in assessing whether adequate evidence was available to support ongoing prescription for individuals under 18 years old.

The primary conclusion was stark: the available evidence did not reach the threshold required to reliably support hormone treatment for this age group. Professor Palmer indicated that the review “demonstrated that the evidence base does not support the continued use of hormone treatments” to treat young people under 18 with gender dysphoria or gender incongruence. This conclusion indicated NHS England could not say whether the therapies were beneficial or detrimental, requiring a pause awaiting more research and professional consultation.

• Ten distinct analyses analyzed various dimensions of hormonal therapy
• Research examined life quality and mental health outcomes
• Available evidence found inadequate to justify ongoing treatment
• Cannot determine if therapies harm or benefit adolescents

Public Response and Legal Battles

The NHS choice to suspend hormone prescriptions has prompted swift and polarised responses from across the healthcare and advocacy sectors. Trans advocacy groups have expressed strong opposition to the policy change, with some organisations signalling their intention to pursue legal action against NHS England. These groups contend that the pause limits availability to potentially life-changing treatment for young people with gender dysphoria, and maintain that the evidence review does not justify such a limiting stance. The consultation period beginning Monday will be vital in establishing whether NHS England’s position evolves or hardens based on stakeholder input.

Healthcare specialists working in gender identity programs have also weighed in on the decision, with views spanning from cautious support to major worries. Some clinicians welcome the evidence assessment as a essential measure to ensure treatments are properly justified, while others express concern that the pause may harm vulnerable young people who have commenced hormone therapy or are waiting to access care. The 90-day review period represents an opportunity for these different stakeholders to put forward their perspectives, possibly affecting whether the temporary pause turns into permanent policy or is adjusted based on new evidence or professional consensus.

Advocacy Group Statement

Trans advocacy groups have condemned the NHS pause as discriminatory and potentially damaging to young people in vulnerable situations. These groups argue that the decision to halt additional prescriptions conflicts with the testimonies of transgender youth who report improved mental health and life quality after hormone therapy. They argue that the assessment’s conclusion of “weak evidence” does not justify such a limiting approach, and that the pause practically withholds care to those who need it most while pending complete scientific confirmation that might never emerge.

Legal challenges are expected, with civil rights organisations suggesting they plan to explore court action to reverse or amend the treatment suspension. These groups maintain that the policy violates the rights of adolescents to access appropriate medical care and might represent discrimination based on gender identity. They stress that individual clinical assessments ought to decide treatment eligibility as opposed to across-the-board bans, and that the engagement process must genuinely consider evidence from trans individuals themselves about personal experiences with hormone therapy.

Commercial Sector and International Context

While NHS England implements its measured approach, the private medical industry in the UK continues to offer hormone treatments to teenagers outside the NHS framework. This establishes a stratified healthcare model where wealthier families may obtain treatments that the NHS has suspended, raising concerns about fairness and availability. The difference between NHS policy and private healthcare delivery draws attention to wider considerations about how evidence-based recommendations should work across different healthcare settings, and whether teenagers’ ability to access to gender-affirming treatments should depend on their family’s economic circumstances rather than medical necessity.

Internationally, healthcare systems have implemented different strategies to hormone treatment for young people questioning their gender. Some European countries, including Sweden and Finland, have similarly tightened restrictions on cross-sex hormones for minors in the past several years, pointing to a lack of evidence. Conversely, other nations maintain more liberal prescribing policies, with some medical organisations contending that withholding care causes greater psychological harm. These differing global approaches underscore the genuine scientific uncertainty regarding the lasting impacts and advantages of these interventions, and suggest that no consensus yet exists among global medical authorities on the appropriate treatment pathway for young people experiencing gender dysphoria.

• Private clinics in the UK persist in providing hormonal therapy to young people despite NHS pause
• Finland and Sweden have likewise limited hormonal medications for minors in recent years
• International medical organisations continue to disagree on suitable therapeutic approaches for adolescents

What’s Next

NHS England has initiated a systematic approach to establish its long-range strategy on hormonal therapy for young people exploring their gender identity. A 90-day public consultation launched on Monday will seek input from patient representatives, clinical experts, and the broader community on the evidence review findings and proposed revised guidance. The health service has highlighted that this engagement process is essential for identifying any evidence that may have been overlooked during the original assessment. The outcomes will directly shape whether the current pause on new prescriptions becomes long-term policy or whether prescribing resumes under adjusted guidelines.

During the consultation period, NHS England will maintain oversight of young people currently undergoing hormone treatment, with clinicians conducting individualised reviews of each patient’s care plan. The three established NHS gender clinics for children will broaden their scope of alternative forms of care for those without access to hormones, including psychological services and therapeutic support. Upon completion of the 90-day period, NHS England will assess all input received and make a final decision regarding long-term policy. This decision will have substantial impact for thousands of young people across England accessing gender-affirming care.

The 90 Day Consultation Process

The consultation constitutes a formal opportunity for stakeholders to challenge or support NHS England’s preliminary findings. Advocacy groups, healthcare practitioners, and members of the general public can provide evidence and viewpoints on whether the review correctly represents current scientific understanding. Trans advocacy organisations have previously signalled they may take legal action, suggesting the consultation will be disputed. NHS England has stated it will carefully review all responses, specifically aiming to find any robust evidence that the initial review may have missed or underweighted in its analysis.

The 90-day window is designed to balance the need for comprehensive deliberation with the urgency of providing transparency to young people and medical professionals presently uncertain about access to treatments. NHS England will gather and review all submissions before releasing its final decision on new guidance. This longer timeframe allows clinicians to voice professional insights, academic bodies to present additional evidence, and young people themselves to articulate how the policy changes affect their overall health and wellbeing.